W. Siegert et al., ANGIOIMMUNOBLASTIC LYMPHADENOPATHY (AILD)-TYPE T-CELL LYMPHOMA - PROGNOSTIC IMPACT OF CLINICAL OBSERVATIONS AND LABORATORY FINDINGS AT PRESENTATION, Annals of oncology, 6(7), 1995, pp. 659-664
Background: In order to establish the clinico-pathological properties
of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma, we
evaluated the type, incidence and prognostic significance of clinical
and laboratory symptoms.Patients and methods: Sixty-two consecutive pa
tients diagnosed at the Kiel lymph node registry participated in the s
tudy. The median patient age was 64 years (range 21-87 years) and the
female to male ratio was 1:1.4. Ninety percent of the patients were in
stage III and IV and B-symptoms were observed in 68%. At diagnosis pa
tients presented with skin rash (49%), pruritus (32%), edema (38%), pl
eural effusion (37%), arthritis (18%) and ascites (23%). Furthermore,
they exhibited autoimmune phenomena such as cold agglutinines, circula
ting immune complexes, a positive Coombs test, smooth muscle antibodie
s, rheumatoid factors, immune hemolysis, a paraprotein, antinuclear an
tibodies and cryoglobulins. Results: In univariate analysis, survival
was significantly related to age (p = 0.032), stage (p = 0.037), B sym
ptoms (p = 0.007), rash/pruritus (p = 0.038), edema (p = 0.030), ascit
es (p = 0.013), number of clinical symptoms including B symptoms (p =
0.004) and excluding B symptoms (p = 0.017), lactate dehydrogenase (p
= 0.007) and hemoglobin (p = 0.020). Conclusions: AILD type T-cell lym
phoma characteristically differs from other non-Hodgkin's lymphomas in
its clinical signs and laboratory symptoms.